Press Releases | BIOJECT -- Needle-Free Injection Technology

2012

Date	Title
01/17	Bioject Retains Financial Advisor to Explore Strategic Alternatives

2011

Date	Title
11/10	Bioject Announces Change in President and Chief Executive Officer
11/08	Bioject Reports Third Quarter 2011 Financial Results
10/24	FDA Communication on Use of Jet Injectors with Influenza Vaccines
09/12	Bioject ZetaJet to be Utilized by Publix for Flu Season Immunizations
09/07	Fred Meyer to Offer Needle-Free Flu Vaccines for First Time
08/10	Bioject Reports Second Quarter 2011 Financial Results (Audio)
08/10	Bioject Reports Second Quarter 2011 Financial Results
08/03	Bioject to Report Second Quarter 2011 Financial Results
06/13	2011 Shareholder's Meeting
06/09	2011 Shareholder's Meeting (Audio)
06/02	Notice of Annual Shareholder Meeting
05/11	Bioject Reports First Quarter 2011 Financial Results (Audio)
05/11	Bioject Reports First Quarter 2011 Financial Results
05/04	Bioject to Report First Quarter 2011 Financial Results
04/22	2010 Annual Report and Proxy
03/25	Fourth Quarter and Fiscal Year 2010 Results (Audio)
03/23	Bioject Reports Fourth Quarter and Year-End 2010 Financial Results
03/17	Bioject to Report Fourth Quarter and Year-End 2010 Financial Results
02/09	Bioject Announces Collaboration to Provide Needle-free Pen Injector for Intradermal Delivery Studies

2010

Date	Title
11/10	Bioject Reports Third Quarter 2010 Financial Results
11/03	Bioject to Report Third Quarter 2010 Financial Results
09/28	Biojector®2000 Utilized in a Human Clinical Trial of DNA-MVA HIV Vaccine
08/05	Bioject Reports Second Quarter 2010 Financial Results (Audio)
08/04	Bioject Reports Second Quarter 2010 Financial Results
07/28	Bioject to Report Second Quarter 2010 Financial Results
07/08	Bioject’s Intradermal Needle-Free Delivery System Used in World Health Organization Clinical Trial in Oman with Poliovirus Vaccine
06/10	2010 Annual Meeting of Shareholders (Audio)
06/04	Bioject Medical Technologies Inc. Annual Shareholder Meeting Thursday, June 10, 2010
05/13	Bioject Reports First Quarter 2010 Financial Results (Audio)
05/12	Bioject Reports First Quarter 2010 Financial Results
05/05	Bioject to Report First Quarter 2010 Financial Results
04/28	Bioject Announces Results of Intradermal Dose Sparing Influenza Study Conducted by the Centers for Disease Control and Prevention
04/27	Bioject Announces Results from US Navy Study for a Malaria Vaccine
04/26	2009 Annual Report
04/26	2010 Proxy
04/07	Bioject Meets Final Development Milestone for Merial Ltd
03/17	Bioject Reports December 31, 2009 Results
02/22	Cyto Pulse, the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Voluntee rs
02/16	MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine
01/05	Bioject Establishes Strategic Alliance with MPI Research

2009

Date	Title
12/21	Bioject Closes Previously Announced Equity Financing
11/05	Bioject Reports Third Quarter 2009 Results (Audio)
11/04	Bioject Reports Third Quarter 2009 Results
10/30	Bioject to Report Third Quarter 2009 Financial Results
08/06	Bioject Reports Second-Quarter 2009 Financial Results (Audio)
08/05	Bioject Reports Second-Quarter 2009 Financial Results
05/06	Bioject Reports First Quarter 2009 Financial Results
05/05	Bioject Signs CRADA with US Navy to Study a Malaria Vaccine
04/14	Bioject Meets Milestone for Merial Limited
04/06	Bioject Announces FDA Market Clearance for the Zetajet™ Needle-Free Injection Therapy System
03/27	Fourth Quarter and Year-End 2008 Financial Results (Audio)
03/25	Bioject Reports December 31, 2008 Results
02/24	Bioject Enters into a Collaborative Research Agreement with IAVI for the Delivery of an HIV Vaccine Candidate
02/10	Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.

2008

Date	Title
12/09	SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
11/10	Bioject Reports Third-Quarter 2008 Results
11/06	U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
08/19	Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
08/06	Bioject Reports Second-Quarter 2008 Financial Results
07/22	Bioject to Be Transferred to the over-the-Counter Bulletin Board
07/17	Biojector®2000 Data Presented in Vical’s Pandemic Influenza DNA Vaccine Human Trial
06/23	Bioject Announces Long-Term Agreement With Merial Limited
06/05	Bioject and ImmunoVaccine Technologies Announce Research Collaboration
05/27	Biojector®2000 Technology Put to the Test in CDC Flu Vaccine Study
05/23	Bioject Receives Nasdaq Staff Detemination
05/07	First Quarter 2008 Earnings Release
03/17	Bioject Reports December 31, 2007 Results and Initiates New Strategy